Am J Transplant, Volume 22, Suppl 3 Archives - Page 185 of 190 - ATC Abstracts

2022 American Transplant Congress
Phase I/ii Car-Treg Cell Therapy Clinical Trial To Induce Long-term Tolerance In Liver Transplant Patients
A. Sanchez-Fueyo¹, A. Taylor¹, D. Collin², C. Nathalie², S. Chris², M. Martinez-Llordella², N. Belmonte², I. McGill², D. Hartl²
¹King's College London, London, United Kingdom, ²Quell Therapeutics Ltd, London, United Kingdom
*Purpose: Life-long pharmacological immunosuppression (IS) is considered essential to prevent rejection following liver transplantation (LT), but is associated with significant side effects such as infections,…
2022 American Transplant Congress
Establishing a Framework for Long-Term Follow-Up: A Survey of Perspectives and Preferences of Living Kidney Donors
S. K. Singh¹, N. Caton², O. Johnston², C. S. Hanson³, A. Dominello³, K. Yetzer⁴, D. Chang², A. Tong³, J. S. Gill²
¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Sydney School of Public Health, University of Sydney, Sydney, Australia, ⁴Canadian Blood Services, Ottawa, ON, Canada
*Purpose: There is currently no established standard for long-term follow-up of living kidney donors in Canada. To inform a new national standard, we sought to…
2022 American Transplant Congress
Predictors of Response to Belatacept Conversion in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection
D. Kumar¹, R. Winstead¹, H. Iftikhar¹, R. Minniti¹, S. Khorsandi¹, J. Christensen¹, I. Yakubu¹, I. Moinuddin¹, L. Kamal¹, P. Halloran², G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²University of Alberta, Edmonton AB, AB, Canada
*Purpose: Chronic active antibody mediated rejection (cABMR) is a major cause of kidney transplant (KT) loss. Current therapies have unclear efficacy and side effects. We…
2022 American Transplant Congress
Variation in Adult Living Donor Liver Transplantation in the United States: Identifying Opportunities for Increased Utilization
K. Lentine¹, D. Axelrod², M. Schnitzler¹, R. Li¹, M. Dew³, T. Bitterman⁴, K. Olthoff⁴, J. Locke⁵, S. Emre⁶, H. Hunt⁷, T. Tanaka², A. Liapakis⁶
¹Saint Louis University, St. Louis, MO, ²U Iowa, Iowa City, IA, ³U Pittsburgh, Pittsburgh, PA, ⁴U Penn, Philadelphia, PA, ⁵UAB, Birmingham, AL, ⁶Yale, New Haven, CT, ⁷UNOS, Richmond, VA
*Purpose: To assess barriers to living donor liver transplant (LDLT) access in light of convincing evidence of survival benefits for patients with end-stage liver disease.*Methods:…
2022 American Transplant Congress
Prescription Opioid Use May be More Detrimental to Younger Kidney Transplant Recipients: A Machine Learning Approach
J. Kim¹, S. Bae¹, J. Ahn¹, K. Lentine², D. Segev¹, M. McAdams-DeMarco¹
¹Johns Hopkins, Baltimore, MD, ²Saint Louis University, St. Louis, MO
*Purpose: Prescription opioid use requires special attention in kidney transplant (KT) recipients considering that it increases the risk of death and graft loss. However, the…
2022 American Transplant Congress
Ex Vivo Modification of Vascular Allografts Using Immunosuppressive and Anti-Inflammatory Polymers Prevent Rejection via Localized Immunosuppression
H. D. Luo¹, E. M. Siren¹, W. Enns², L. Sim¹, C. Du¹, S. G. Withers¹, J. Choy³, J. N. Kizhakkedathu¹
¹The University of British Columbia, Vancouver, BC, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
*Purpose: Classical immunosuppressants lead to systemic immune shutdown, though necessary to mediate transplant rejection, it may lead to various complications. To reduce off-target immunosuppression while…
2022 American Transplant Congress
Targeting the Bet Family Protein Brd4 Inhibits Inflammatory Macrophages and Promotes Heart Allograft Tolerance
X. Xiao
Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: Infiltration of allografts by inflammatory macrophages is frequently associated with chronic graft loss In both animal models and clinical settings, but the mechanisms that…
2022 American Transplant Congress
Outcomes of Hlai Kidney Transplants in Patients with Cpra 100% After Desensitization
A. A. Vo¹, J. Tang¹, S. Williamson¹, C. Meyers¹, E. Huang¹, X. Zhang², M. Haas³, A. Peng¹, R. Najjar¹, S. Supreet¹, N. Ammerman¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ²HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: The KAS implementation was aimed at increasing access to kidney transplantation in highly HLA sensitized (HS) patients. However, combining desensitization (DES) + KAS could…
2022 American Transplant Congress
18 Month Impact of the National Liver Review Board
J. Foutz¹, S. Noreen¹, K. Bradbrook², M. Cafarella¹, J. Pomposelli³, S. Biggins⁴, J. Trotter⁵
¹United Network for Organ Sharing, Richmond, VA, ²Research, United Network for Organ Sharing, Richmond, VA, ³University of Colorado, Aurora, CO, ⁴University of Washington, Seattle, WA, ⁵Baylor University Medical Center, Dallas, TX
*Purpose: The National Liver Review Board (NLRB) was implemented 5/14/2019, establishing a national structure for liver exceptions comprised of three specialty review boards and a…
2022 American Transplant Congress
Delayed Graft Function in Living Donor Kidney Transplantation: Risk Factors and Outcomes
G. Defelice¹, A. Paramesh², H. Jeon², K. Atiemo², M. Killackey², A. Vijay²
¹Tulane University School of Medicine, New Orleans, LA, ²Transplant Surgery, Tulane University School of Medicine, New Orleans, LA
*Purpose: Delayed graft function (DGF) following living donor kidney transplantation is less common and long-term outcomes are less understood. This single-center retrospective analysis of living…